GLIOMATCH is a Horizon Europe project with the ambition of pioneering targeted brain cancer treatment. KU Leuven leads the GLIOMATCH consortium uniting over a dozen pan-European partners from 10 different member states.
KU Leuven is home to the Laboratory for Precision Cancer Medicine, attached to the Translational Cell and Tissue Research Unit of the Department of Imaging and Pathology and the Leuven Institute for Single-cell Omics, focused on precision matching of cancer treatments with patients.
In alignment with Europe’s Beating Cancer Plan, GLIOMATCH addresses the EU Cancer Mission‘s four objectives: understanding cancer, prevention and early detection, diagnosis and treatment, and quality of life for patients and their families
Brain tumours are amongst the most lethal forms of cancer types, causing profound distress for individuals and their families and imposing a burden on communities and healthcare systems. By making technology for customised treatments available to clinicians, GLIOMATCH aims to alleviate this burden.
The prospects for patients of all ages suffering from glioblastoma are bad and have barely improved over the past three decades.
Patients and tumours are extremely heterogeneous and clinicians lack valuable information required for matching patients with the most effective treatments.
A platform for clinicians, which continuously integrates and evaluates years worth of data from glioblastoma patients, can significantly improve patient care.
Prof. Frederik De Smet from KU Leuven,
GLIOMATCH project coordinator
On the 10th anniversary of the International Day of Women and Girls in Science, GLIOMATCH celebrates the women driving our research and our commitment to gender balance in science and leadership.
On World Cancer Day 2025, the GLIOMATCH project participated in the EU project showcase hosted by HaDEA, highlighting the role of EU-funded research in advancing cancer care. We have seized this opportunity to map the EU Cancer Mission project landscape.
The GLIOMATCH project has received ethical approval from the UZ/KU Leuven Ethics Committee to conduct retrospective clinical trials for adult and paediatric glioma patients. This follows earlier approvals for other project partners, setting data collection to begin in 2025,.
